Pharus Sicav Medical Innovation

Class A
ISIN: LU1491986011
Category: Sector Equity Biotechnology
22.06.2022
Key Information
Net Asset Value117,04 EUR
Fund Size11.309.013 EUR
Launch Date 2 ott 2012
BenchmarkBENCHMARK COMPOSITE 17389
Key Information
Management information
SicavPHARUS SICAV
Management CompanyPHARUS MANAGEMENT LUX SA
Investment ManagerPharus Asset Management SA
Key Information
Investment objective
The fund's objective is to achieve capital growth by investing in equity or similar securities issued by biopharmaceutical companies, mainly belonging to the American small cap niche, at the forefront of medical innovation, active in the research of new drugs or in possession of interesting technologies for the development of new therapies. The fund is characterized by strong growth trends both in the short term and in the medium to long term and embraces technological innovation, which allows companies to streamline processes and grow at ever greater speeds. The stock selection process is rigorous and is based on a top-down approach, which starts with the identification of the therapeutic areas of interest, such as for example oncology, orphan and neurological diseases, and then proceeds to equally weight the main players, for a total of 150-200 securities.
Key Information

Risk & reward profile

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
22.06.2022
Manager comment
Manager comment
The fund recorded a negative performance of -7.10% in May. The fund invests in companies in the pharmaceutical, medical and biotechnology sectors, with a particular interest in the latest technological and scientific innovations. Specifically, the fund focuses on small and mid-cap companies, pursuing high diversification through a portfolio of over 150 names. We remain focused on the US market, maintaining full hedging against the Euro / US Dollar exchange rate. Despite the heavy corrections in recent months, we believe the fund represents an excellent investment opportunity in the medium to long term, as the fundamentals of the companies have not deteriorated and today there are very attractive valuations for one of the sectors that will certainly prove to be be one of the key drivers of the next few years. Significant in this sense was the acquisition of Biohaven Pharmaceuticals by the American giant Pfizer for 11.6 billion dollars. This could represent the beginning of a new round of investments by the big players in the Pharma sector, which have a level of liquidity sufficient to acquire the entire American Biotech small-cap segment.
Documents
N.A.

Last updated on 22.06.2022

* No coverage or derivatives are included
* No coverage or derivatives are included
Top Ten Holding
Invesco Nasdaq Biotech 2.96 %
Halozyme Therapeutics Inc 1.44 %
United Therapeutics Corp 1.41 %
Turning Point Therapeutics I 1.37 %
Alkermes Plc 1.33 %
Dynavax Technologies Corp 1.32 %
Biohaven Pharmaceutical Hold 1.31 %
Vir Biotechnology Inc 1.28 %
Vertex Pharmaceuticals Inc 1.23 %
Ionis Pharmaceuticals Inc 1.23 %
Top Ten Holding
How to invest